Latest News

Energy Transfer and The Williams Companies are all solid midstream plays.

You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.

It recently signed a deal with an AI hyperscaler.

A lower price alone is not enough to make a stock a buying opportunity.

The business is on the cusp of accelerating revenue growth.

The best business in the world could make a poor investment if the price is too high.

The deal makes sense for both sides of the equation.

Amazon is investing in assets that generate higher-margin returns.

The AI chipmaker is about the size Nvidia's data center business was nearly a decade ago. Can it grow the same way?

Because I own stocks like these, I don't worry about my brokerage statements, even though I'm invested in sectors that are currently out of favor.

Sales are down, guidance has been rough, and with oil and interest rates rising, what is the future for the consumer?

Arm commands smartphone architecture and is moving into AI CPUs; Marvell dominates data center connectivity with 32.6% net margins.

The neocloud company is a rising star, but the hyperscaler has a massive head start.

After a few years of stagnation, this stock is soaring.

Social Security's cost-of-living adjustment (COLA) for 2027 is expected to be announced Oct. 14. What might it mean for you?

Canopy pursues a lean U.S.-focused strategy while Tilray has diversified into beverages, but their diverging paths and financial profiles reveal starkly different risk-reward profiles for 2026.

Some of the world's most important artificial intelligence (AI) stocks are noticeably absent from the S&P 500.

Firefly's hypergrowth masks massive cash burn, while Rocket Lab trades at a premium despite better financial discipline. One valuation gap may matter more than you think.

This AI networking specialist is growing like a weed, but its future rests on a handful of very big customers. Here's what the next three years could bring.

Nvidia is primed to benefit from the massive ongoing AI build-out.

Both companies are unprofitable and burning cash, but their paths to scale, and valuations, tell strikingly different stories.

It can make sense to check out what big investors are doing with their money.

VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.

At one time, Bitcoin had 1,000x upside potential. But is that still the case?

Ward's purchase through his revocable trust brings his aggregate stake to 28.4 million units, representing a 17.0% ownership interest in the energy partnership.